Cargando…

Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis

BACKGROUND AND OBJECTIVES: In a phase 1 amyotrophic lateral sclerosis (ALS) study, autologous infusions of expanded regulatory T-lymphocytes (Tregs) combined with subcutaneous interleukin (IL)-2 were safe and well tolerated. Treg suppressive function increased and disease progression stabilized duri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thonhoff, Jason R., Berry, James D., Macklin, Eric A., Beers, David R., Mendoza, Patricia A., Zhao, Weihua, Thome, Aaron D., Triolo, Fabio, Moon, James J., Paganoni, Sabrina, Cudkowicz, Merit, Appel, Stanley H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423710/ https://www.ncbi.nlm.nih.gov/pubmed/36038262 http://dx.doi.org/10.1212/NXI.0000000000200019

Ejemplares similares

Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study
por: Thonhoff, Jason R., et al.
Publicado: (2018)

Serum programmed cell death proteins in amyotrophic lateral sclerosis
por: Beers, David R., et al.
Publicado: (2021)

Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis
por: Beers, David R., et al.
Publicado: (2020)

Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis
por: Beers, David R., et al.
Publicado: (2011)

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival
por: Henkel, Jenny S, et al.
Publicado: (2013)

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival
por: Henkel, Jenny S, et al.
Publicado: (2013)

Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease
por: Thome, Aaron D., et al.
Publicado: (2021)

Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial
por: Smith, Richard, et al.
Publicado: (2017)

Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS
por: Beers, David R., et al.
Publicado: (2022)

Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation
por: Thome, Aaron D., et al.
Publicado: (2022)

Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis
por: Nicholson, Katharine, et al.
Publicado: (2018)

Military Service and Amyotrophic Lateral Sclerosis in a Population-based Cohort
por: Weisskopf, Marc G., et al.
Publicado: (2015)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes
por: Paganoni, Sabrina, et al.
Publicado: (2022)

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability
por: Berry, James D., et al.
Publicado: (2017)

Serum Ferritin and Metal Levels as Risk Factors for Amyotrophic Lateral Sclerosis
por: Qureshi, Muddasir, et al.
Publicado: (2008)

Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion
por: Faridar, Alireza, et al.
Publicado: (2020)

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
por: Goyal, Namita A., et al.
Publicado: (2020)

Antibody Response to HML‐2 May Be Protective in Amyotrophic Lateral Sclerosis
por: Garcia‐Montojo, Marta, et al.
Publicado: (2022)

Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial
por: Babu, Suma, et al.
Publicado: (2021)

Functional alterations of myeloid cells during the course of Alzheimer’s disease
por: Thome, Aaron D., et al.
Publicado: (2018)

Cromolyn sodium delays disease onset and is neuroprotective in the SOD1(G93A) Mouse Model of amyotrophic lateral sclerosis
por: Granucci, Eric J., et al.
Publicado: (2019)

Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls
por: Zhao, Weihua, et al.
Publicado: (2020)

Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis
por: Alshikho, Mohamad J., et al.
Publicado: (2016)

Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis
por: Berry, James D., et al.
Publicado: (2013)

IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis
por: Wosiski-Kuhn, Marlena, et al.
Publicado: (2019)

Improving clinical trial outcomes in amyotrophic lateral sclerosis
por: Kiernan, Matthew C., et al.
Publicado: (2020)

An expanded access protocol of RT001 in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor
por: Yerton, Megan, et al.
Publicado: (2022)

Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS
por: Wills, Anne Marie, et al.
Publicado: (2019)

Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis
por: Salter, Matthew, et al.
Publicado: (2018)

Developing multidisciplinary clinics for neuromuscular care and research
por: Paganoni, Sabrina, et al.
Publicado: (2017)

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses
por: Miller, Robert G., et al.
Publicado: (2022)

Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry’s Research Notification Mechanism
por: Mehta, Paul, et al.
Publicado: (2021)

Clinical Significance of TDP-43 Neuropathology in Amyotrophic Lateral Sclerosis
por: Cykowski, Matthew D., et al.
Publicado: (2017)

Apolipoprotein B-100-mediated motor neuron degeneration in sporadic amyotrophic lateral sclerosis
por: Wong, Jamie K, et al.
Publicado: (2022)

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [(11)C]-PBR28
por: Zürcher, Nicole R., et al.
Publicado: (2015)

Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery
por: Gwinn, Katrina, et al.
Publicado: (2007)

Adjusted cost analysis of video televisits for the care of people with amyotrophic lateral sclerosis
por: Paganoni, Sabrina, et al.
Publicado: (2019)

TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis
por: Cykowski, Matthew D, et al.
Publicado: (2014)

Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease
por: Faridar, Alireza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5m7llcillkqmekgjda0fhpoj0j